Innovative BBB Models HUREL's integration into Visikol has expanded its portfolio to include advanced in vitro BBB assays and BBB models, presenting significant opportunities to develop and supply novel permeability testing solutions and biochemical materials for neuropharmacology and CNS drug development.

Cutting-edge Imaging Services Recent launches of multiplex tissue imaging and imaging mass cytometry services in a GLP setting indicate a strong demand for high-throughput, multiparametric imaging technologies, offering prospects to partner or provide specialized reagents, dyes, and imaging instrumentation.

Tissue Model Expansion The development and commercialization of human and animal kidney and liver tissue slice models open sales avenues for precision tissue samples, reagents, and tools tailored for preclinical efficacy, toxicity testing, and personalized medicine applications.

Strong Industry Collaborations Partnerships with industry leaders like Standard BioTools strengthen Visikol's imaging capabilities, creating opportunities to offer complementary products such as advanced imaging reagents, assay kits, and automation tools to enhance the research services.

Growing Market Presence With a revenue range of up to $25 million and recent service launches, Visikol is positioning itself as a competitive player in the biotechnology research space, indicating potential for upselling high-throughput screening solutions, custom assays, or service packages to biotech and pharma clients seeking innovation and reliability.